The headache specialist at Hartford Healthcare Headache Center emphasized the importance of avoiding unnecessary fear surrounding the potential link between migraine and dementia, as current evidence does not strongly support it being a significant risk factor. [WATCH TIME: 2 minutes]
The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]
The director of the Movement Disorders Division at Loma Linda University discussed the importance of understanding good ON time in Parkinson disease care, and how it can influence quality of life. [WATCH TIME: 5 minutes]
Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Jun Li, MD, PhD, of Houston Methodist Hospital. [WATCH TIME: 3 minutes]
The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute discussed the questions that still remain with identifying and treating subarachnoid hemorrhage. [WATCH TIME: 3 minutes]
The vice dean for data science at Duke University School of Medicine spoke about the major disparities observed in models that assess stroke risk. [WATCH TIME: 4 minutes]
The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]
Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.
The lead neuroscientist and lead data scientist at Rune Labs talked about leveraging mobility data to monitor progression in patients with Parkinson disease. [WATCH TIME: 7 minutes]
The senior research scientist at the Institute for Systems Biology spoke about changing the perception of clinical trials for Alzheimer disease research based on the COCOA trial presented at the 2022 CTAD conference. [WATCH TIME: 2 minutes]
The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]
The general neurologist at Brigham and Women’s Hospital described the approach and mindset in teaching neurology as the field continuously evolves. [WATCH TIME: 3 minutes]
The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]
The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]
The chief training and education officer at the Parkinson’s Foundation discussed the inclusion of various medical professionals that assist in Parkinson disease care, and the need to provide access to educational tools to inform clinicians. [WATCH TIME: 5 minutes]
In our latest roundtable series, experts discussed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.
The research scientist at Kessler Foundation discussed a recently funded study focused on improving memory and learning deficits in patients with multiple sclerosis by combining a cognitive rehabilitation program with a cycling initiative enriched with virtual reality elements. [WATCH TIME: 7 minutes]
In this episode of Connecting ALS, Dave R. Zook, JD, an advisor with expertise in federal regulatory policy, speaks to the process of making drug coverage decisions for newly approved therapies.
A duo of experts provide insight on various topics related to the advances in treatment options, diagnosis of the disorder, role of genetics, and potential future research and gene therapies.
The behavioral neurologist at NYU Langone Health and chief medical officer at Isaac Health shared his reaction to the recent approval of donanemab for patients with Alzheimer disease. [WATCH TIME: 7 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
The associate professor of neurology at the University of Texas Health Science Center at Houston talked about advances in the classification of inflammatory myopathies at the recently concluded 2023 MDA conference. [WATCH TIME: 4 minutes]
In a paradigm with many options, once multiple sclerosis is confirmed as a patient’s diagnosis, physicians are left with 1 question: What do we choose for long-term treatment?
With many patients presenting with an unknown time of last known well, establishing a tissue window using advanced imaging techniques may allow for more effective intervention and better outcomes.
Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.
The professor of neurology at Cedars-Sinai Medical Center shared his thoughts on potential therapies that expand management care options for patients with neuromuscular disease, in particularly for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 4 minutes]
Episode 28 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and David Lee Gordon, MD, FAAN, FANA, FAHA, of University of Oklahoma. [WATCH TIME: 8 minutes]
The health economics outcomes research specialist at UCB discussed the need for improved methodologies to have a more accurate analysis of patient outcomes beyond what administrative databases can provide. [WATCH TIME: 2 minutes]
The research scientist at NYU Langone Health talked about findings from preclinical data investigating epileptiform activity in mouse models of Alzheimer disease, which were presented at AES 2023. [WATCH TIME: 4 minutes]
The chief diversity, equity and inclusion officer at the Alzheimer’s Association discussed the findings of the association’s special edition of its annual Facts and Figures report.